MediciNova Inc (NASDAQ:MNOV) has completed half of its phase II trial for ibudilast, its new treatment for multiple sclerosis,
Out of 255 enrolled patients, 127 have now completed the 96-week treatment period.
The trial’s external Data Safety Monitoring Board will review the results of an interim efficacy analysis in the fourth quarter ahead of making a recommendation to the National Institute of Neurological Diseases and Stroke (NINDS).
Yuichi Iwaki, MediciNova’s chief executive, said: "We are very pleased to have reached the 50% completion milestone in this important study.
“The unmet medical need for progressive MS patients is extremely high as there is no treatment approved for long-term use for these patients.”
The trial is being carried out across 28 enrolling clinical sites across the US and will evaluate the safety, tolerability and efficacy of MN-166 (ibudilast) administered twice daily to subjects with primary or secondary progressive multiple sclerosis.